• <menu id="888u4"><menu id="888u4"></menu></menu>
  • Radiotherapy and Chemotherapy in Advanced Non-Small Cell Lung Cancer

    Closed for proposals

    Project Type

    Coordinated Research Project

    Project Code

    E33029

    CRP

    1465

    Approved Date

    19 September 2007

    Status

    Closed

    Start Date

    1 December 2007

    Expected End Date

    31 December 2013

    Completed Date

    10 October 2013

    Description

    Treatment of locally advanced and metastatic NSCLC is an important issue in radiation oncology worldwide, especially for low and middle income countries where up to 70-80% of all cancer patients are treated through palliative approach. In both locally advanced and metastatic NSCLC, palliation and quality of life are major goals of radiation therapy. By optimizing fractionation of radiotherapy and evaluating the role of chemotherapy in a resource sparing combined modality approach in NSCLC, it is expected that Member States will benefit from the rational use of existing equipment and staff levels, decreasing costs, yet providing optimal treatment for patients. It is also expected that this effort could lead to wide adoption of the resource sparing fractionation regimen in radiotherapy centres, promoting awareness of the necessity to perform shorter fractionation regimens and/or shorter chemotherapy regimens in this setting worldwide.

    Objectives

    The overall objective of the CRP is to optimize the treatment of locally
    advanced and metastatic nonsmall cell lung cancer (NSCLC). This objective will
    be achieved by
    a) comparing survival after irradiation alone to that obtained with a combined
    chemotherapy and radiotherapy in locally advanced NSCLC (Study A) and
    b) by comparing chemotherapy alone to a combined radiotherapy and
    chemotherapy in metastatic NSCLC (Study B).
    These two questions refer not only to find out which is the optimal treatment,
    but also have an implication in adequate use of resources. If there are not
    significant differences, the assessment on QOL will be essential to define the
    better option.

    Specific objectives

    To assess differences in quality of life (QOL) between the two regimens
    investigated for both locally advanced and metastatic NSCLC (Study A and
    Study B).

    To compare a low-dose palliative thoracic radiotherapy of either 10 Gy in a
    single fraction or 16 Gy in two fractions given with one week split against 2-3
    cycles of chemotherapy, radiotherapy being followed by the same
    chemotherapy in patients with metastatic NSCLC (Study B).

    To compare toxicity between the two regimens investigated for both locally
    advanced and metastatic NSCLC (Study A and Study B).

    To study the efficacy of high-dose palliative thoracic radiotherapy of 39 Gy in
    13 daily fractions compared to a 2-3 cycles of chemotherapy followed by a
    low-dose palliative thoracic radiotherapy of either 10 Gy in a single fraction or
    16 Gy in two fractions given with one week split in patients with locally
    advanced NSCLC (Study A).

    Impact

    Adoption of the short RT schedule (study A) will result in efficient utilization of existing infrastructure which is relevant in MS with limited resources and with problems to RT access.

    Relevance

    Treatment of locally advanced and metastatic NSCLC is an important issue in radiation oncology worldwide, especially for low and middle income countries where up to 70-80% of all cancer patients are treated with palliative intent.

    CRP Publications

    Stay in touch

    Newsletter

    午夜爱爱爱爱爽爽爽视频网站